Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| Epithalon | Longevity | Not approved | None established | — | — | C | View |
| FOXO4-DRI | Longevity | Not approved | None established | — | — | C | View |
| Humanin | Longevity | Not approved | None established | — | — | C | View |
| L-Glutathione | Longevity | Not approved | None established | Oral, sublingual, intravenous and nebulized inhalation in the human studies reviewed | — | B | View |
| Methylene Blue | Longevity | FDA-approved | 1 mg/kg (FDA label); repeat 1 mg/kg once if needed | Intravenous over 5 to 30 minutes | Approximately 24 hours | A | View |
| N-Acetyl Epithalon Amidate | Longevity | Not approved | None established | — | — | — | View |
| NAD+ | Longevity | Not approved | None established | Intravenous infusion in the one published human study of NAD+ itself | — | B | View |
| P-21 | Longevity | Not approved | None established | — | — | C | View |
| SS-31 (Elamipretide) | Longevity | FDA-approved | 40 mg once daily (FORZINITY label, patients weighing at least 30 kg); 20 mg once daily in adults with eGFR below 30 mL/minute not on dialysis | Subcutaneous injection | — | A | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.